Inclusion Criteria:

          -  Male or female participant aged ≥ 18 years old

          -  Participants with cytologically confirmed and documented treatment naïve, de novo or
             secondary AML defined by WHO 2016 classification (Arber, 2016). Secondary AML
             includes:

               -  Previous myelodysplastic syndrome transformed

               -  AML due to exposure to potentially leukemogenic therapies or agents (e.g.
                  radiation therapy, alkylating agents, topoisomerase II inhibitors) with the
                  primary malignancy in remission for at least 3 years

          -  Participants not eligible for standard induction chemotherapy

               -  Aged ≥ 75 years old

               -  Or Age ≥18 years with at least one of the following comorbidities:

                    -  Clinically significant heart or lung comorbidities, as reflected by at least
                       one of:

                         -  Lung diffusing capacity for carbon monoxide (DLCO) ≤65% of expected

                         -  Forced expiratory volume in 1 second (FEV1) ≤65% of expected

                    -  Other contraindication(s) to anthracycline therapy (must be documented)

                    -  Other comorbidity that the Investigator judges as incompatible with
                       intensive remission induction chemotherapy, which must be documented

          -  ECOG (Eastern Cooperative Oncology Group) performance status should be (criterion
             should be rechecked at inclusion visit) ECOG ≤ 2.

          -  Written informed consent obtained prior any study-specific procedure as described in
             section 13.3 of the protocol.

          -  Adequate renal and hepatic function

          -  Circulating White Blood Cell Count (WBC count) < 25*109 G/L (with or without use of
             hydroxycarbamide/leukapheresis)

          -  Serum potassium, serum calcium, serum phosphates, serum magnesium within normal limits
             with or without supplementation.

        Exclusion Criteria:

          -  Major surgery within 3 weeks prior to the first IMP administration, or participants
             who have not recovered from side effects of the surgery

          -  Any radiotherapy within 3 weeks before the first IMP administration,

          -  Allogenic stem cell transplant within 3 months before the first IMP administration
             and/or participants with active Graft-versus-host disease within 3 months before the
             first IMP administration and/or participants who still receive immunosuppressive
             treatment within 3 months before the first IMP administration and/or participant who
             receive donor lymphocyte infusion (DLI) within 3 months before the first IMP
             administration

          -  Acute promyelocytic leukemia (APL, French-American-British M3 classification)

          -  Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per
             the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2016 for Acute
             Myeloid Leukemia

          -  Treatment with hypomethylating agents (decitabine/azacitidine) or Venetoclax for AHD
             (antecedent hematologic disorders) in the 3 months prior to the first IMP intake